It’s time to beat cancer
Vigeo is a clinical-stage biopharmaceutical company developing novel therapeutics that can effectively treat multiple types of cancer and improve the lives of patients.
Vigeo is a clinical-stage biopharmaceutical company developing novel therapeutics that can effectively treat multiple types of cancer and improve the lives of patients.
Vigeo is currently developing therapies that target the TIME by activating thrombospondin-1 (Tsp-1), a naturally occurring potent anti-tumorigenic protein, and one of the body’s own defenses against cancer. Tsp-1 has been shown to attack cancer cells and to prevent their spread through metastasis via CD36 and CD47 pathways.
We are currently studying VT1021, a peptide therapeutic agent in clinical trials enrolling patients in pancreatic, ovarian, triple negative breast cancers, glioblastoma, and tumors with high amounts of CD36.
July 06, 2022
January 20, 2022
November 16, 2021